表紙
市場調査レポート

女性の健康:米国の骨粗鬆症の管理市場における動向と機会

Women's Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

発行 Medtech Insight 商品コード 289909
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
女性の健康:米国の骨粗鬆症の管理市場における動向と機会 Women's Health: Trends and Opportunities in the U.S. Osteoporosis Management Market
出版日: 2013年09月30日 ページ情報: 英文 150 Pages
概要

米国では、人口の高齢化に伴って、骨粗鬆症が大幅に増加することが予測されています。その患者数は、骨粗鬆症が約900万人、低骨量が4,800万人以上と推計されています。

当レポートでは、米国の骨粗鬆症の診断・治療製品市場について調査分析し、製品、競合企業、市場機会について検証して、概略以下の構成でお届けいたします。

第1章 骨粗鬆症の概要

  • 発症率、有病率、コスト
  • 骨粗鬆症の種類
  • リスク因子

第2章 骨密度測定製品市場

  • 骨密度測定の概要
  • 骨密度測定製品
  • 償還
  • 市場分析
  • 競合分析

第3章 骨再形成生化学マーカー検査市場

  • 生化学マーカーの概要
  • 生化学マーカー検査製品
  • 償還
  • 市場分析
  • 競合分析

第4章 骨粗鬆症治療薬市場

  • 臨床の概要
  • 市場分析
  • 競合分析

第5章 企業プロファイル

  • The Cooper Companies, Inc.
  • GE Healthcare/General Electric Company
  • Hologic, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holding AG

付録

目次
Product Code: A331

In the United States (U.S.), the rate of osteoporosis is expected to grow significantly as the population ages. It is estimated that approximately 9 million adults in the U.S. have osteoporosis and more than 48 million have low bone mass, placing them at risk for developing osteoporosis. Assuming that prevalence of osteoporosis and low bone mass remains unchanged, by the year 2020, it is projected that 10.7 million adults in the U.S. will have osteoporosis and 58.2 million will have low bone mass.

This dynamic new report from Medtech Insight includes analyses of products, competitors, and opportunities in the U.S. market for osteoporosis diagnosis and treatment products. During the forecast period covered by this report, the U.S. market for osteoporosis management products is projected to grow to an estimated $6.4 billion by the year 2017. This market, as covered by the scope of this report, includes diagnostic products (including bone densitometry systems and bone remodeling biochemical marker tests) and current and emerging pharmaceutical treatments (including bisphosphonates, estrogen agonists/antagonists, estrogen and estrogen/progestin therapies, monoclonal antibody inhibitors, salmon calcitonin, and synthetic parathyroid hormone).

Table of Contents

EXECUTIVE SUMMARY

  • i. Osteoporosis Incidence and Prevalence
  • ii. Osteoporosis Diagnosis and Management
    • a. Bone Densitometry
    • b. Biochemical Markers
    • c. Pharmaceutical Treatments
  • iii. Market Analysis
    • a. Bone Densitometry Systems
    • b. Biochemical Markers
    • c. Pharmaceutical Treatments
  • i. Estrogen/Hormone Therapy Drugs
  • ii. Osteoporosis Drugs
  • iv. Methodology
  • Exhibit ES-1: 2012, Osteoporosis-Caused Fracture Incidence, by Site
  • Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2012-2017
  • Exhibit ES-3: Bone Densitometry Systems, Market Forecast, 2012-2017
  • Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017
  • Exhibit ES-5: Pharmaceutical Treatments for Osteoporosis, Market Forecast, 2012-2017
  • Exhibit ES-6: 2012, Pharmaceutical Treatments for Osteoporosis, Sales by Product Category

1. OVERVIEW OF OSTEOPOROSIS

  • 1.1. Incidence, Prevalence, and Cost
  • 1.2. Types of Osteoporosis
  • 1.3. Risk Factors
  • Exhibit 1-1: Osteoporotic Bone and Normal Bone
  • Exhibit 1-2: 2012, Osteoporosis-Caused Fracture Incidence, by Site
  • Exhibit 1-3: Osteoporosis or Low Bone Mass in Women Age 50 and Older, by Race and Ethnicity
  • Exhibit 1-4: Types of Osteoporosis
  • Exhibit 1-5: Leading Risk Factors for Osteoporosis

2. BONE DENSITOMETRY PRODUCTS MARKET

  • 2.1. Bone Densitometry Overview
    • 2.1.1. Dual-Energy X-Ray Absorptiometry
    • 2.1.2. Single-Energy X-Ray Absorptiometry
    • 2.1.3. Radiographic Absorptiometry
    • 2.1.4. Quantitative Computed Tomography
    • 2.1.5. Quantitative Ultrasound
    • 2.1.6. Hospital-Based Densitometry Systems
    • 2.1.7. Office-Based Densitometry Systems
    • 2.1.8. Software-Based Densitometry Systems
  • 2.2. Densitometry Products
    • 2.2.1. BeamMed
    • 2.2.2. CompuMed
    • 2.2.3. CooperSurgical/The Cooper Companies
    • 2.2.4. Furuno USA/Furuno Electric Company
    • 2.2.5. GE Healthcare/General Electric Company
    • 2.2.6. Hologic
    • 2.2.7. Lone Oak Medical Technologies
    • 2.2.8. Sectra
  • 2.3. Reimbursement
  • 2.4. Market Analysis
  • 2.5. Competitive Analysis
  • Exhibit 2-1: Comparison of Biochemical Markers and Bone Densitometry as Tools for Diagnosing and Monitoring Osteoporosis
  • Exhibit 2-2: Imaging Technologies Used to Diagnose Osteoporosis
  • Exhibit 2-3: 2013, Selected Bone Densitometry Systems
  • Exhibit 2-4: The Sunlight MiniOmni Bone Sonometer
  • Exhibit 2-5: The Norland Family of Dual-Energy X-Ray Absorptiometry Systems
  • Exhibit 2-6: The Lunar iDXA Dual-Energy X-Ray Absorptiometry System
  • Exhibit 2-7: The Discovery Dual-Energy X-Ray Absorptiometry System
  • Exhibit 2-8: The OsteoGram Radiographic Absorptiometry System
  • Exhibit 2-9: The CM-200 Quantitative Ultrasound Bone Densitometry System
  • Exhibit 2-10: The Accudxa2 Dual-Energy X-Ray Absorptiometry System
  • Exhibit 2-11: Hospital-Based Bone Densitometry Systems, Market Forecast, 2012-2017
  • Exhibit 2-12: Office-Based Bone Densitometry Systems, Market Forecast, 2012-2017
  • Exhibit 2-13: Total Bone Densitometry Systems, Market Forecast, 2012-2017
  • Exhibit 2-14: 2012, Bone Densitometry Systems Market, Share by Supplier

3. BONE REMODELING BIOCHEMICAL MARKER TESTS MARKET

  • 3.1. Biochemical Markers Overview
    • 3.1.1. Types of Bone Turnover Markers
    • 3.1.2. Applications
  • 3.2. Biochemical Marker Testing Products
    • 3.2.1. Alere
    • 3.2.2. Beckman Coulter
    • 3.2.3. Roche Diagnostics/Roche
    • 3.2.4. Immunodiagnostic Systems
    • 3.2.5. Orion Diagnostica/Orion Group
    • 3.2.6. Quidel
  • 3.3. Reimbursement
  • 3.4. Market Analysis
  • 3.5. Competitive Analysis
  • Exhibit 3-1: The Bone Remodeling Cycle
  • Exhibit 3-2: Comparison of Selected Bone Remodeling Biochemical Marker Tests
  • Exhibit 3-3: 2013, Selected Bone Remodeling Biochemical Marker Tests
  • Exhibit 3-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017
  • Exhibit 3-5: 2012, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier

4. OSTEOPOROSIS PHARMACEUTICAL TREATMENTS MARKET

  • 4.1. Clinical Overview
    • 4.1.1. Antiresorptive Drugs
      • 4.1.1.1. Bisphosphonates
        • 4.1.1.1.1. Alendronate
        • 4.1.1.1.2. Ibandronate
        • 4.1.1.1.3. Risedronate
        • 4.1.1.1.4. Zoledronate
      • 4.1.1.2. Salmon Calcitonins
        • 4.1.1.2.1. Novartis
        • 4.1.1.2.2. Unigene Laboratories
        • 4.1.1.2.3. Emerging Drugs
      • 4.1.1.3. Estrogen/Hormone Therapy
      • 4.1.1.4. Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors
      • 4.1.1.5. Estrogen Agonists/Antagonists
        • 4.1.1.5.1. Emerging Drugs
          • 4.1.1.5.1.1. Pfizer
          • 4.1.1.5.1.2. EndoCeutics
      • 4.1.1.6. Other Emerging Antiresorptives
        • 4.1.1.6.1. Cathepsin K Inhibitors
        • 4.1.1.6.2. Monoclonal Antibodies
          • 4.1.1.6.2.1. Alethia Biotherapeutics
          • 4.1.1.6.2.2. Novo Nordisk
    • 4.1.2. Bone-Forming Drugs
      • 4.1.2.1. Synthetic Parathyroid Hormone
        • 4.1.2.1.1. Forteo
        • 4.1.2.1.2. Pipeline Drugs
          • 4.1.2.1.2.1. Radius Health
      • 4.1.2.2. Other Emerging Anabolic Drugs
        • 4.1.2.2.1. Serotonin Inhibitors
    • 4.1.3. Bone Morphogenetic Proteins
    • 4.1.4. Dual-Action Bone Agents
      • 4.1.4.1. Strontium Ranelate
      • 4.1.4.2. Strontium Malonate
    • 4.1.5. Gene Therapy
  • 4.2. Market Analysis
    • 4.2.1. Estrogen/Hormone Therapy Drugs
    • 4.2.2. Osteoporosis Drugs
      • 4.2.2.1. Bone-Building Drugs
      • 4.2.2.2. Bisphosphonates
      • 4.2.2.3. Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors
      • 4.2.2.4. Salmon Calcitonin
  • 4.3. Competitive Analysis
  • Exhibit 4-1: 2013, Selected Pharmaceutical Treatments for Osteoporosis
  • Exhibit 4-2: 2013, Selected Emerging Pharmaceutical Treatments for Osteoporosis
  • Exhibit 4-3: Estrogen/Hormone Therapy and Osteoporosis Drugs, Market Forecast, 2012-2017
  • Exhibit 4-4: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs, Sales by Product Category
  • Exhibit 4-5: United States Patent Status of Selected Estrogen/Hormone Therapy Drugs
  • Exhibit 4-6: United States Patent Status of Selected Osteoporosis Drugs
  • Exhibit 4-7: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs Market, Share by Supplier

5. COMPANY PROFILES

  • 5.1. Alere, Inc.
  • 5.2. The Cooper Companies, Inc.
  • 5.3. GE Healthcare/General Electric Company
  • 5.4. Hologic, Inc.
  • 5.5. Eli Lilly and Company
  • 5.6. Novartis AG
  • 5.7. Pfizer, Inc.
  • 5.8. Roche Holding AG

APPENDIX: COMPANY LISTING

Back to Top